Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis - Takeaways - MDSpire

Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis

  • By

  • Chengwu Lu

  • Libao Zhang

  • Changhui Xue

  • Mingxin Liao

  • Jichang Fei

  • Xiaojun Chen

  • Linfeng Wang

  • May 8, 2026

  • 0 min

Share

  • 1

    The network meta-analysis included 21 RCTs with 4,409 men to compare the efficacy and safety of anti-osteoporotic agents for primary osteoporosis.

  • 2

    Teriparatide and abaloparatide significantly improved femoral neck bone mineral density compared to placebo, with oral bisphosphonates also showing benefits.

  • 3

    For total hip bone mineral density, oral bisphosphonates demonstrated greater improvements than teriparatide, while both agents showed significant gains.

  • 4

    Abaloparatide and teriparatide yielded larger gains in lumbar spine bone mineral density compared to oral bisphosphonates and placebo.

  • 5

    Safety evidence was limited and imprecise, highlighting the need for further high-quality RCTs focusing on fracture outcomes and adverse events.

Original Source(s)

Comparative efficacy and safety of odanacatib, abaloparatide, denosumab, teriparatide, and bisphosphonates for male osteoporosis: a systematic review and network meta-analysis

  • by Chengwu Lu, Libao Zhang, Changhui Xue, Mingxin Liao, Jichang Fei, Xiaojun Chen, Linfeng Wang

  • May 8, 2026

Related Content

A Nomogram for Predicting Low Bone Mineral Density in the Elderly Using Chest CT

MAFLD is associated with lower bone mineral density in patients with type 2 diabetes: an exploratory cross-sectional analysis of a potential indirect association with HOMA-IR

Second contralateral hip fractures reduce survival, mobility and daily activity : a matched pair analysis